Recurrent C. diff infection is when you contract a C. diff infection 2 to 8 weeks after completing treatment for a previous one. C. diff relapse is a recurrence of the same strain, while reinfection ...

Please provide your email address to receive an email when new articles are posted on . Clostridioides difficile infection presents a unique treatment paradox for clinicians: Antibiotics are often ...

C. diff infection can cause diarrhea. While it may lead your poop to change color, there are no specific colors that are definitive evidence of having C. diff. According to the Centers for Disease ...

Researchers have identified two distinct mechanisms of drug resistance in C. difficile, but its ability to withstand antibiotics comes with downsides for the bacteria. When you purchase through links ...

A recent Centers for Disease Control and Prevention report found 75 percent of patients in a group of 10,342 cases were already colonized with C. difficile at the time of hospital admission, according ...

Crestone Pharmaceuticals recently shared topline results from a phase 2 trial of its investigational drug treatment for Clostridioides difficile infection. Investigators evaluated the safety and ...

Mass General Brigham researchers at two hospitals found the metabolic strategies C. difficile uses to rapidly colonize the gut and identified ways to combat the disease, the Somerville, Mass.-based ...

The bacterium Clostridioides difficile is one of the most common infections picked up in hospitals, and, even once it’s cleared from the body, patients have a 1 in 6 chance of catching it again within ...

A toxoid vaccine candidate against Clostridioides difficile failed to reduce the incidence of infection in at-risk adults ages 50 and older, according to results of the phase III CLOVER trial. Of ...

A synthetic microbiome therapy, tested in mice, protects against severe symptoms of a gut infection that is notoriously difficult-to-treat and potentially life threatening in humans, according to a ...

(RTTNews) - Acurx Pharmaceuticals, Inc. (ACXP) Monday announced that its lead antibiotic candidate, ibezapolstat, is advancing to international Phase 3 clinical trials for treating C. difficile ...

Fecal microbiota transplantation (FMT), shown to be effective in the treatment of recurrent Clostridioides difficile infection (CDI), also shows significant benefit in the treatment of primary CDI, ...